Conditions

Outcome Measures

Percent of Participants With Progression Free Survival (PFS) After 1 Year Treatment
PFS is defined as the rate at 1 year from the date of first dose of study drug to the first date of measured PD or death from any cause and was determined using the distribution of overall PFS times. The PFS rate at 1 year was determined using Kaplan-Meier estimates. For participants not known to have died as of the data cut-off date and who do not have PD, PFS was censored at the date of the last progression-free disease assessment.
First Dose of Study Drug to Measured Progressive Disease or Death from Any Cause at 1 Year

Overall Response Rate (ORR) - Percentage of Participants Achieving Complete Response (CR) or Complete Response Unconfirmed (CRu) or Partial Response (PR) (Response)
Baseline to Measured Progressive Disease or Death from Any Cause at End of 4 and 8 Cycles
Percent of Participants With Progression-Free Survival (PFS) After 2 Years and 4 Years of Treatment
First Dose of Study Drug to Measured Progressive Disease or Death from Any Cause at 2 Years, 4 Years
Percent of Participants With Overall Survival (OS) After 1 Year, 2 Years and 4 Years
First Dose of Study Drug to Death from Any Cause at 1 Year, 2 Years and 4 Years
Percent of Participants With Event Free Survival (EFS) After 1 Year, 2 Years and 4 Years
First Dose of Study Drug to Measured PD, or Start of New Lymphoma Treatment or Death from Any Cause at 1 Year, 2 Years and 4 Years
Progression-Free Survival (PFS ) of Participants With Diffuse Large B-cell Lymphoma (DLBCL) Germinal-Center B-cells (GCB) Versus Non-GCB Molecular Subtypes (Assessment of Biomarkers Relevant for Enzastaurin)
Baseline, Cycles 1-4, End of Study
+5 more secondary outcomes

EXPERIMENTAL

Drug: enzastaurinDrug: gemcitabineDrug: rituximabDrug: oxaliplatin

1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years

Also known as: LY317615

Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)

1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles

Also known as: LY188011, Gemzar

Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)

375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles

Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)

100 mg/m², IV, once every two weeks, four to eight 2 week cycles

Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)

Age60 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Diagnosis of DLBCL or transformed (cluster differentiation 20 \[CD20\]+) indolent lymphoma
Relapsed/progressed after response obtained in 1st- or 2nd-line treatment, or participants who have not progressed after stable disease (SD) obtained in 1st- or 2nd-line.
Measurable disease (lymph node greater than 1.5 cm)
Adequate organ function
Greater than or equal to 60 years or less than 60 (but greater than or equal to 18 years) who are not eligible for high-dose chemotherapy high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT)

Contact the study team to confirm eligibility.